Trials / Completed
CompletedNCT00298896
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Sunesis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the objective tumor response rate to SNS-595 in patients with small cell lung cancer (SCLC).
Detailed description
Other objectives of this study are to assess the safety, survival rate, best response, time to disease progression, duration of tumor response, and to explore several potential biomarkers to see how these levels change after administration of SNS-595.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SNS-595 |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2007-08-01
- Completion
- 2008-06-01
- First posted
- 2006-03-03
- Last updated
- 2018-07-26
- Results posted
- 2018-07-26
Locations
17 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00298896. Inclusion in this directory is not an endorsement.